ResearcherUniversity of TurinActive in the last 2 years
Francesco Leone
Matched on ORCID iD 0000-0001-5422-9706; OpenAlex author ID A5022734154. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 1, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 38
2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 9
- A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemothe… Co-author DOI 10.1016/j.dld.2025.11.007↗
- Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. Co-author DOI 10.3390/cancers15030900↗
- Corrigendum to ""Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic can… Last author DOI 10.1016/j.critrevonc.2020.102867↗
- Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. First author DOI 10.1016/j.clcc.2019.08.004↗
- "Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer. Last author DOI 10.1016/j.critrevonc.2018.10.009↗
- Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? Co-author DOI 10.3390/cancers11101547↗
- Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? Co-author DOI 10.1016/j.critrevonc.2017.03.025↗
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Last author DOI 10.1093/annonc/mdu205↗
- Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatme… Co-author DOI 10.1002/cncr.27736↗
Closest collaborators
The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Massimo Aglietta · 6 shared papers, 2013–2020 · strength 0.46
- Paper Corrigendum to ""Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated i… DOI 10.1016/j.critrevonc.2020.102867↗
- Paper "Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for s… DOI 10.1016/j.critrevonc.2018.10.009↗
- Paper Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? DOI 10.3390/cancers11101547↗
- Pasquale Lombardi · 4 shared papers, 2019–2020 · strength 0.39
- Paper Corrigendum to ""Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated i… DOI 10.1016/j.critrevonc.2020.102867↗
- Paper "Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for s… DOI 10.1016/j.critrevonc.2018.10.009↗
- Paper Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? DOI 10.3390/cancers11101547↗
- Caterina Vivaldi · 3 shared papers, 2019–2025 · strength 0.38
- Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
- Paper Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evid… DOI 10.3390/cancers15030900↗
- Paper Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxali… DOI 10.1016/j.clcc.2019.08.004↗
- Lorenzo Fornaro · 2 shared papers, 2019–2023 · strength 0.22
- Paper Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evid… DOI 10.3390/cancers15030900↗
- Paper Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxali… DOI 10.1016/j.clcc.2019.08.004↗
- Francesco Montagnani · 2 shared papers, 2019–2023 · strength 0.22
- Paper Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evid… DOI 10.3390/cancers15030900↗
- Paper Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxali… DOI 10.1016/j.clcc.2019.08.004↗
- Enrico Vasile · 2 shared papers, 2019–2023 · strength 0.22
- Paper Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evid… DOI 10.3390/cancers15030900↗
- Paper Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxali… DOI 10.1016/j.clcc.2019.08.004↗
- Emanuela Dell’Aquila · 2 shared papers, 2017–2025 · strength 0.22
- Mario Scartozzi · 2 shared papers, 2017–2023 · strength 0.21
- Giuseppe Aprile · 2 shared papers, 2017–2023 · strength 0.21
- Federico Nichetti · 1 shared paper, 2025 · strength 0.16
- Elisa Giommoni · 1 shared paper, 2025 · strength 0.16
- Silvia Bozzarelli · 1 shared paper, 2025 · strength 0.16
- Francesca Bergamo · 1 shared paper, 2025 · strength 0.16
- Ingrid Garajová · 1 shared paper, 2025 · strength 0.16
- Ilario Giovanni Rapposelli · 1 shared paper, 2025 · strength 0.16
- Carolina Sciortino · 1 shared paper, 2025 · strength 0.16
- Gianluca Tomasello · 1 shared paper, 2025 · strength 0.16
- Monica Niger · 1 shared paper, 2025 · strength 0.16
- Lisa Salvatore · 1 shared paper, 2025 · strength 0.16
- Valentina Fanotto · 1 shared paper, 2023 · strength 0.15
- Debora Basile · 1 shared paper, 2023 · strength 0.15
- Elisabetta Fenocchio · 1 shared paper, 2019 · strength 0.10
- Déwi Vernerey · 1 shared paper, 2019 · strength 0.07
- Cindy Neuzillet · 1 shared paper, 2019 · strength 0.07
- Angélique Vienot · 1 shared paper, 2019 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.